Rankin Aubrey 4
4 · Revance Therapeutics, Inc. · Filed Jul 30, 2021
Insider Transaction Report
Form 4
Rankin Aubrey
DirectorPresident, Innovation & Tech
Transactions
- Sale
Common Stock
2021-07-28$30.15/sh−20,000$603,000→ 154,302 total(indirect: By Trust) - Sale
Common Stock
2021-07-28$30.00/sh−34,332$1,029,960→ 321,611 total(indirect: By Trust)
Holdings
- 79,776
Common Stock
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Rankin.
- [F2]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.02. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]These shares are held by the Aubrey and Luanne Rankin Revocable Living Trust dated July 1, 2009. Mr. Rankin is a Trustee of this Trust.
- [F4]The sales by the Rankin Irrevocable Trust (the "Trust") reported in this Form 4 were effected pursuant to an executed instruction letter previously provided to the Company by the trustee of the Trust.
- [F5]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.01 to $30.35. Mr. Rankin undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]These shares are held by The Rankin Irrevocable Trust, of which the children of Mr. Rankin are beneficiaries.